Prevalence of COPD and comorbidity

European Respiratory Monograph

Volumn 59, Issue , 2013, Pages 1-12

  Aryal, Shambhu ^a   Diaz Guzman, Enrique ^a   Mannino, David M ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Comorbidity; COPD; Human pathology; Outcomes; Prevalence

Indexed keywords

ANTIDEPRESSANT AGENT; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; ASTHMA; CACHEXIA; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; DEATH; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; ECONOMIC ASPECT; FIBROSING ALVEOLITIS; HAZARD RATIO; HEART DISEASE; HUMAN; HYPERTENSION; LENGTH OF STAY; LUNG CANCER; LUNG EMBOLISM; MENTAL DISEASE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OSTEOPENIA; OSTEOPOROSIS; PNEUMONIA; PREVALENCE; PSYCHOTHERAPY; QUESTIONNAIRE; SLEEP DISORDERED BREATHING;

EID: 84874857068     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10011012     Document Type: Article

References (61)

1. Global Strategy for the Diagnosis, Management, and Prevention of COPD. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). 2011. Available from www.goldcopd.com Date last updated: February 21, 2012. Date last accessed: August 2012.
2. Celli BR, MacNee W, Agusti A. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
3. Celli BR, Halbert RJ, Isonaka S, et al. Population impact of different definitions of airway obstruction. Eur Respir J 2003; 22: 268-273.
4. Pellegrino R, Viegi G, Brusasco C, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968.
5. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 502-506.
6. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-773.
7. Franchi M. EFA Book on chronic obstructive pulmonary disease in Europe. Sharing and Caring. Brussels, European Federation of Airway Diseases, 2010.
8. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366: 1875-1881.
9. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28: 523-532.
10. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.
11. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997; 349: 1498-1504.
12. Rycroft CE, Heyes A, Lanza L, et al. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis 2012; 7: 457-494.
13. Di Bonaventura Md., Paulose-Ram R., Su J., et al. The burden of chronic obstructive pulmonary disease among employed adults. Int J Chron Obstruct Pulmon Dis 2012; 7: 211-219.
14. Dalal AA, Liu F, Riedel AA. Cost trends among commercially insured and medicare advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009. Int J Chron Obstruct Pulmon Dis 2011; 6: 533-542.
15. National Heart, Lung, and Blood Institute. Fact book Fiscal Year 2006. Bethesda, NIH/NHLBI, 2007.
16. Rijcken B, Britton J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir Monogr 1998; 7: 74-83.
17. Nielsen R, Johannessen A, Benediktsdottir B, et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study. Eur Respir J 2009; 34: 850-857.
18. Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 627-643.
19. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155-161.
20. Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences clinical impact, mechanisms, and potential for early intervention. COPD 2008; 5: 235-256.
21. Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 549-555.
22. Loscalzo J. System's biology and personalized medicine: a network approach to human disease. Proc Am Thorac Soc 2011; 8: 196-198.
23. Barnes PJ. COPD: inflammatory mechanisms and systemic consequences. Eur Respir Monogr 2013; 59: 13-27.
24. Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in chronic obstructive pulmonary disease: a casecontrol study in a health maintenance organization. Arch Intern Med 2000; 160: 2653-2658.
25. van Manen JG, Bindels PJ, IJzermans CJ, et al. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 2001; 54: 287-293.
26. Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128: 2099-2107.
27. Sidney S, Sorel M, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068-2075.
28. Anecchino C, Rossi E, Fanizza C, et al. Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population. Int J Chron Obstruct Pulmon Dis 2007; 2: 567-574.
29. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
30. Cazzola M, Bettoncelli G, Sessa E, et al. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010; 80: 112-119.
31. Agusti A, Calverley PMA, Celli B, et al. Characterization of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.
32. Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke, a comprehensive analysis using data from primary care. Thorax 2010; 65: 956-962.
33. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16: 63-70.
34. Marin JM, Soriano JB, Carrizo SJ, et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea, the overlap syndrome. Am J Respir Crit Care Med 2010; 182: 325-331.
35. Aryal S, Diaz-Guzman E, Mannino DM. Treatment options in asthma and chronic obstructive pulmonary diseases overlap syndrome. Eur Respir Dis 2011; 7: 101-105.
36. Pifarre R, Falguera M, Vicente-de-Vera C, et al. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 2007; 101: 2139-2144.
37. Calverley PM, Anderson JA, Celli B, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
38. Lieberman D, Lieberman D, Gelfer Y, et al. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 2002; 122: 1264-1270.
39. Tillie-Leblond I, Marquette CH, Perez T, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006; 144: 390-396.
40. Rutschmann OT, Cornuz J, Poletti PA, et al. Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease? Thorax 2007; 62: 121-125.
41. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32: 1371-1385.
42. Weitzenblum E, Chaouat A, Kessler R, et al. Overlap syndrome: obstructive sleep apnea in patients with chronic obstructive pulmonary disease. Proc Am Thorac Soc Am Thorac Soc 2008; 5: 237-241.
43. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of COPD using the new GOLD classification. A study of the general population. Am J Respir Crit Care Med 2012; 186: 975-981.
44. Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009; 122: 348-355.
45. Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204-212.
46. Lawes CM, Thornley S, Young R, et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J 2012; 21: 35-40.
47. Patel AR, Hurst JR. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med 2011; 5: 647-662.
48. Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151-1156.
49. Mannino DM, Aguayo SM, Petty TL, et al. Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003; 163: 1475-1480.
50. Wasswa-Kintu S, Gan WQ, Man SF, et al. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 2005; 60: 570-575.
51. van Gestel YR, Hoeks SE, Sin DD, et al. COPD and cancer mortality: the influence of statins. Thorax 2009; 64: 963-967.
52. Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 2008; 134: Suppl. 4, 43S-56S.
53. Hanania NA, Mullerova H, Locantore NW, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011; 183: 604-611.
54. Incalzi RA, Corsonello A, Pedone C, et al. Chronic renal failure, a neglected comorbidity of COPD. Chest 2010; 137: 831-837.
55. Johnston AK, Mannino DM, Hagan GW, et al. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax 2008; 63: 599-605.
56. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
57. McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD, operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62: 411-415.
58. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-339.
59. Kinnunen T, Saynajakangas O, Tuuponen T, et al. Impact of comorbidities on the duration of COPD patients' hospital episodes. Respir Med 2003; 97: 143-146.
60. Roberts CM, Stone RA, Lowe D, et al. Co-morbidities and 90-day outcomes in hospitalized COPD exacerbations. COPD 2011; 8: 354-361.
61. Lin PJ, Shaya FT, Scharf SM. Economic implications of comorbid conditions among Medicaid beneficiaries with COPD. Respir Med 2010; 104: 697-704.